Redx Pharma (REDX) Hits New 1-Year Low at $13.25

Redx Pharma PLC (LON:REDX)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 13.25 ($0.18) and last traded at GBX 14 ($0.19), with a volume of 132750 shares traded. The stock had previously closed at GBX 14 ($0.19).

The company has a market capitalization of $15.74 and a price-to-earnings ratio of -1,400.00.

In related news, insider Iain Ross bought 102,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The stock was acquired at an average cost of GBX 21 ($0.29) per share, with a total value of £21,420 ($29,593.81).

TRADEMARK VIOLATION NOTICE: “Redx Pharma (REDX) Hits New 1-Year Low at $13.25” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at

Redx Pharma Company Profile

Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton’s Tyrosine Kinase (BTK), which has reached candidate nomination stage.

Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply